Abingdon Health PLC Launch of Abingdon Simply Test e-commerce website
21 July 2022 - 4:00PM
RNS Non-Regulatory
TIDMABDX
Abingdon Health PLC
21 July 2022
Abingdon Health plc
("Abingdon" or "the Company")
Launch of Abingdon Simply Test e-commerce website
York, U.K. 21 July 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, announces the launch of its new B2C
e-commerce website, abingdonsimplytest.com .
The Abingdon Simply Test website will provide UK and
international customers with Abingdon Simply Test and
Abingdon-assured third-party branded self-tests. All products will
be regulatory approved and manufactured under international quality
management systems.
The e-commerce site has launched with a range of tests in areas
such as fertility, health and well-being and infectious disease. It
is Abingdon's intention to broaden the range of available tests,
with a focus on self-testing.
The Abingdon Simply Test website will provide consumers with
simple, jargon-free information to enable them to make considered
purchasing decisions. All tests on the abingdonsimplytest.com site
will also have undergone Abingdon's 10-point evaluation covering
quality, regulatory and usability requirements to provide customers
with greater assurance on the quality of these tests.
Self-testing is a major growth area within the global diagnostic
market and in its recent report, Future Market Insights forecast
the global market for self-testing kits will be worth US $11bn by
2030(1) . Lateral flow testing has seen a significant increase in
profile and familiarity following the rapid expansion of COVID-19
lateral flow self-testing during the pandemic. The increased
awareness amongst the general public of lateral flow testing
coupled with its benefits such as low cost and ease-of-use means
that LFT testing will play a major role in the democratisation of
testing and the empowerment of individuals to manage their own
health.
Chris Yates, CEO of Abingdon Health plc, commented: "The
healthcare landscape is changing and the increase in lateral flow
testing during the COVID-19 pandemic has served as a catalyst for a
paradigm shift in moving diagnostic testing out of the laboratory
and into the home. Consumers are increasingly taking a more,
proactive approach to managing their health and wellbeing and this
is leading to the growth of the self-health and self-testing
market. The launch of our Abingdon Simply Test site will provide
focal point for consumers wishing to purchase lateral flow
self-tests and will support people in taking an empowered role in
managing their own health and wellbeing."
(1)
https://www.futuremarketinsights.com/reports/self-testing-market
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Dr Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond, Sam Butcher (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)7867 984
Marriage 082
Alice Woodings Mob: +44 (0)7407 804 654
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of
choice for a growing global customer base and takes projects from
initial concept through to routine and large-scale manufacturing
and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPUPCMUPPGMU
(END) Dow Jones Newswires
July 21, 2022 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024